History
The History of ITM: Advancing Radiopharmaceutical Innovation
For over two decades, we have proudly contributed to the evolution of radiopharmaceuticals through our expertise in isotope manufacturing and radiopharmaceutical development. With a vertically integrated approach, we supply medical radioisotopes while advancing a deep and robust pipeline, including late-stage programs with differentiated approaches to clinically validated targets and early-stage novel programs.
Early Years: Building a Strong Foundation in Isotope Production
ITM began with a focus on producing n.c.a. Lutetium-177 (¹⁷⁷Lu), a key radioisotope used in cancer treatment. Over time, ITM expanded its capabilities in high-purity isotope manufacturing and established collaborations with pharmaceutical partners worldwide. This expertise in isotope production laid the groundwork for our continued contributions to the radiopharmaceutical sector.
While Lutetium-177 (¹⁷⁷Lu) remains widely utilized today, ITM is actively exploring next-generation isotopes, including Actinium-225 (²²⁵Ac), with the potential to enhance patient outcomes.
Expanding into Radiopharmaceutical Drug Development
Building on ITM’s foundation in isotope production, ITM expanded its focus to include radiopharmaceutical drug development. This strategic shift integrates isotope manufacturing with therapeutic innovation, supporting the advancement of radiopharmaceutical treatments from research to clinical application.
ITM’s pipeline today includes multiple assets across various tumor types, reflecting a commitment to broadening therapeutic options in oncology. Ongoing research explores a range of isotopes and targeted approaches to improve treatment outcomes.
Innovation in Radiopharmaceutical Therapy
Beyond isotope production, ITM is engaged in advancing radiopharmaceutical therapy (RPT). Its development pipeline includes late-stage therapeutic candidates progressing through clinical development, as well as early-stage research.
The Evolving Role of Radiopharmaceutical Therapy
Radiopharmaceutical therapy is gaining recognition as an important treatment approach in oncology, with the potential to play a more central role in cancer care.
Looking Ahead
As we continue to advance radiopharmaceutical development, our focus remains on innovation, strategic partnerships, and scientific progress to support improved treatment options for patients. By integrating expertise in isotope manufacturing with radiopharmaceutical research, we are proud to contribute to the evolving landscape of cancer therapy.